1 or, which also serves to form dimers of this
blood coagulation factor.
2 inone to sustain gamma-carboxylation of many
blood coagulation factors.
3 nvolves virus binding to vitamin K-dependent
blood coagulation factors.
4 myelination with deposition of fibrinogen, a
blood coagulation factor abundantly deposited in multipl
5 prothrombin activator, trypsin-like enzymes,
blood coagulation factors and prophenoloxidase cascade a
6 ammalian milk fat globule membrane proteins,
blood coagulation factors,
and receptor tyrosine kinases
7 Elevated circulatory levels of many
blood coagulation factors are known to be a risk factor
8 The major role of peptide hormones,
blood coagulation factors,
carcinogenesis agents, and ot
9 ct of antibodies and mitigate the binding of
blood coagulation factor (
Factor X) in vitro.
10 Some recombinant vitamin K-dependent
blood coagulation factors (
factors VII, IX, and protein
11 Deletion of the
blood coagulation factor fibrinogen largely reversed blo
12 Impaired secretion of an essential
blood coagulation factor fibrinogen leads to hepatic fib
13 or of blood coagulation in vivo and the only
blood coagulation factor for which a human genetic defec
14 eno-associated viral (AAV) vector expressing
blood coagulation factor IX (F.IX) can result in long-te
15 leeding disorder hemophilia B [deficiency in
blood coagulation factor IX (F.IX)] by gene replacement
16 adeno-associated viral (AAV) vector encoding
blood coagulation factor IX (FIX) into skeletal muscle r
17 , we carried out a systematic study on human
blood coagulation factor IX (hFIX) and anti-coagulant pr
18 s for the liver-specific expression of human
blood coagulation factor IX (hFIX).
19 in long-term expression (>5 months) of human
blood coagulation factor IX at levels that were therapeu
20 l carboxylase, it is not stimulated by human
blood coagulation factor IX propeptides.
21 iathesis caused by the absence of functional
blood coagulation factor IX, and is an excellent candida
22 F9, a gene on the X chromosome that encodes
blood coagulation factor IX, and is predicted to alter R
23 y with an adenoviral vector expressing human
blood coagulation factor IX.
24 Blood coagulation factor IXa (fIXa) is a trypsin-like se
25 Blood coagulation factor IXa gains proteolytic efficienc
26 Blood coagulation factor IXa has been presumed to be reg
27 During
blood coagulation, factor IXa (FIXa) activates factor X
28 terature, such as stasis, the derangement in
blood coagulation factor levels and activities, inflamma
29 Spatial distribution of
blood coagulation factors on the surface of procoagulant
30 Activation of
blood coagulation factor V (FV) is a key reaction of hem
31 Blood coagulation factor V circulates as a procofactor w
32 Deficiency of
blood coagulation factor V or tissue factor causes the d
33 r which tracks with reduced plasma levels of
blood coagulation factors V, VII, VIII, IX, X, and XII.
34 In an essential step of
blood coagulation, factor V is proteolytically processed
35 ease, activated protein C (APC), inactivates
blood coagulation factors Va (FVa) and VIIIa.
36 ermal growth factor-like domain (EGF-1) from
blood coagulation factor VII (FVII) contains two unusual
37 ave studied a family with homozygous lethal,
blood coagulation factor VII (FVII) deficiency.
38 The topography of membrane-bound
blood coagulation factor VIIa (fVIIa) was examined by po
39 catalytic activity of a complex composed of
blood coagulation factor VIIa and tissue factor (fVIIa/T
40 Hemophilia A is caused by a deficiency of
blood coagulation factor VIII (FVIII) and has been widel
41 The uptake and processing of
blood coagulation factor VIII (FVIII) by antigen-present
42 tor (LDLR) was shown to mediate clearance of
blood coagulation factor VIII (FVIII) from the circulati
43 Blood coagulation factor VIII (fVIII) is activated by th
44 Development of neutralizing Abs to
blood coagulation factor VIII (FVIII) provides a major c
45 otein that circulates noncovalently bound to
blood coagulation factor VIII (fVIII).
46 which shares homology with the C2 domains of
blood coagulation factor VIII and factor V.
47 The human
blood coagulation factor VIII C2 domain (Ser2173-Tyr2332
48 Blood coagulation factor VIII has a domain structure des
49 a genetic disease caused by a deficiency of
blood coagulation factor VIII or IX.
50 ng disorder that is due to the deficiency of
blood coagulation factor VIII or IX.
51 and expression of a gene encoding functional
blood coagulation factor VIII or IX.
52 , and 23/26del) which cannot bind platelets,
blood coagulation factor VIII, or collagen, causing VWD
53 Deficiency of
blood coagulation Factors VIII, IX, or XI is associated
54 vectors can bind several vitamin K-dependent
blood coagulation factors,
which contributes to virus se
55 raction between the capsid hexon protein and
blood coagulation factor X (FX), whilst penton-alpha(v)i
56 Ad5 transduction requires
blood coagulation factor X (FX); FX binds to the Ad5 cap
57 Blood coagulation Factor X and its activated form Factor
58 sAd24 virions formed unstable complexes with
blood coagulation factor X and, because of that, transdu
59 Blood coagulation factor X plays a pivotal role in the c
60 and tissues, irrespective of the presence of
blood coagulation factor X.
61 ay inhibitor (TFPI) is a potent inhibitor of
blood coagulation factor Xa (fXa) and factor VIIa.
62 directly inhibited the catalytic activity of
blood coagulation factor Xa (fXa), while a third form (A
63 f a series of novel nonpeptide inhibitors of
blood coagulation Factor Xa is described.
64 protein Z (PZ), to regulate the function of
blood coagulation factor Xa on membrane surfaces.
65 was measured in terms of its inactivation of
blood coagulation factor Xa.
66 nctions as a cofactor-dependent regulator of
blood coagulation factors Xa (FXa) and XIa.
67 nctions as a cofactor-dependent regulator of
blood coagulation factors Xa and XIa.
68 In the intrinsic pathway of
blood coagulation factor XIa (FXIa) activates factor IX
69 N) superfamily, is a potent inhibitor of the
blood coagulation Factor XIa (FXIa).
70 ent, reversible and competitive inhibitor of
blood coagulation factor XIa (FXIa).
71 l synthesis of selective inhibitors of human
blood coagulation factor XIIa and thrombin exhibiting a
72 to transamidation by both TG2 and activated
blood coagulation factor XIII (FXIIIa).
73 protease thrombin proteolytically activates
blood coagulation factor XIII by cleavage at residue Arg
74 activity, oligomerization, and stability of
blood coagulation factor XIII.
75 Blood coagulation factor XIIIa is a calcium-dependent en